pharma · Ph+ ALL · Unresectable or Metastatic Melanoma or Advanced Solid Tumors
Ascentage Pharma
Ascentage Pharma Group
Ascentage Pharma Group is a pharma organization headquartered in CN. Primary therapeutic focus areas include Ph+ ALL, Unresectable or Metastatic Melanoma or Advanced Solid Tumors. NovaPharmaNews links 2 clinical program(
USA HQ
2009 Founded
178 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- USA
- Founded
- 2009
- Employees
- 178
- Programs
- 2
- Drugs
- 3
- Patents
- 0
Olverembatinib
Phase 3 · small molecule · Ph+ ALL
Olverembatinib for Ph+ ALL is a Phase 3 program (small_molecule) at Ascentage Pharma Group with 1 ClinicalTrials.gov record(s).
Internal code HQP1351AG301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Ascentage Pharma Group
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Ph+ ALL
- Status
- active
- Trials
- 1